ARTICLE | Emerging Company Profile
CRISPR-based therapies
Intellia has IP to develop CRISPR-based cell and gene therapies
December 8, 2014 8:00 AM UTC
Caribou Biosciences Inc. and Atlas Venture co-founded Intellia Therapeutics LLC to develop gene and cell therapies based on Caribou's CRISPR genome editing technology. Intellia has exclusive rights to CRISPR IP from a co-inventor of the technology, positioning the company to be one of the few developing CRISPR-based therapeutics.
CRISPRs (clustered, regularly interspaced short palindromic repeats) are part of the CRISPR-Cas9 bacterial defense system, which cleaves foreign homologous DNA from the genome...